HZNP - Earnings announcements

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre

Second-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $445.5 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $244.3 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $68.1 Million -- -- Cash Position of $2.5 Billion as of June 30, 2023 -- Second-Quarter and Recent Company Highlights: -- Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) -- -- Obtained U.S. FDA Approva

Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be publicly available on the Investor Relations page of its website at https://ir.horizontherapeutics.com. About Horizon Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and sever

First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $405.3 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $187.0 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $53.8 Million -- -- Cash Position of $2.31 Billion as of March 31, 2023 -- First-Quarter and Recent Company Highlights: -- Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) -- -- Obtained U.S. FDA Approval for Updated TEPEZZA Indication to Specify Treatment of TED Patients Regard

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre

Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be publicly available on the Investor Relations page of its website at https://ir.horizontherapeutics.com. About Horizon Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and sever

Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $493.5 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $216.1 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $41.8 Million -- Full-Year 2022 Results: -- Record Net Sales of $3.63 Billion; Year-Over-Year Increase of 12% -- -- GAAP Net Income of $521.5 Million; Record Adjusted EBITDA of $1.37 Billion; Includes $56.3 Million of Acquired IPR&D and Milestones Expenses -- -- Record TEPEZZA Net Sales of $1.97 Billion; Year-Over-Y